UNSPSC 51372004: Butorphanol

This classification denotes an opioid receptor agonist and opioid with the molecular formula C21H29NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QV897JC36D, chemically known as morphinan-3,14-diol, 17-(cyclobutylmethyl)- but generally known as butorphanol, which bears US NIH Compound Identifier 2487. Butorphanol most often comes in base and tartrate forms. European Medicines Agency schedules Butorphanol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06035MIG.

UNSPSC 51372004 Butorphanol is a Commodity code that covers pharmaceutical products used in emergency response and opioid-crisis mitigation, though the recent state and local contracting activity under this code reflects broader procurement of naloxone and related drug-intervention systems rather than butorphanol specifically. State and local health departments, county public health agencies, and community health authorities are the primary issuing bodies under this code, seeking to acquire opioid-antagonist medications and drug deactivation systems to support emergency medical services, harm-reduction initiatives, and community health programs. The work involves sourcing pharmaceutical supplies and related equipment on a recurring, often multi-year contract basis with provisions for quarterly or annual deliveries, compliance with federal and state pharmacy regulations, and integration into existing county or municipal health infrastructure.

Seminole County, Florida recently posted an IFB (Invitation for Bids) for naloxone and safe drug deactivation systems in June 2026, seeking 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The IFB required electronic bid submission, E-Verify compliance, drug-free workplace certification, and specified insurance requirements including workers' compensation and commercial general liability coverage; bidders were required to include all shipping and delivery costs in their proposals, and the contract included a three-month probationary period and potential FEMA funding with corresponding federal compliance obligations. The recent Florida activity represents the primary visible state and local procurement signal under this code; broader geographic distribution of butorphanol or naloxone procurement remains limited in the available opportunity records.